洛比那韦
羟基氯喹
医学
2019年冠状病毒病(COVID-19)
利托那韦
大流行
临床试验
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
肺炎
不利影响
法维皮拉维
药理学
重症监护医学
病毒学
内科学
病毒载量
人类免疫缺陷病毒(HIV)
抗逆转录病毒疗法
疾病
传染病(医学专业)
作者
Shubham Atal,Shilpa N. Kaore
出处
期刊:Current drug research reviews
[Bentham Science]
日期:2022-11-01
卷期号:14 (3): 203-214
被引量:5
标识
DOI:10.2174/2589977514666220527105158
摘要
Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity. It has initiated an era of research on repurposed drugs such as hydroxychloroquine, lopinavir/ritonavir, corticosteroids, remedesivir, ivermectin, alongside selective antivirals to treat or prevent COVID- 19. Molnupiravir is an orally available emerging antiviral drug considered highly promising for COVID-19. Methods and results: We have performed a scoping review for the use of molnupiravir against SARS-CoV-2 and COVID-19. It acts by inhibiting RNA-dependent RNA polymerase (RdRp), and exhibits broad-spectrum antiviral activity. Preclinical studies have evaluated the therapeutic efficacy as well as prophylactic activity of molnupiravir against SARS CoV-2 in various animal models that include ferrets, hamsters, mice, immunodeficient mice implanted with human lung tissue and cell cultures, in various doses ranging from 5-300 mg/kg, and results have been encouraging. Initial evidence of safety and efficacy from early phase clinical studies has been encouraging too, and recent results from a large phase 3 global trial have shown significant benefits among symptomatic outpatients. Other late-phase clinical trials are still underway with the aim of establishing molnulpiravir as a therapeutic option for COVID-19, particularly for non-hospitalized patients. Conclusions and Relevance: On the basis of the limited evidence available as of now, molnupiravir could prove to be a promising oral therapy, worthy of further exploration of its utility for both treatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted to confirm whether the results are replicable to the clinical scenario among outpatients to reduce the chance of progression to more severe disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI